CysLT1 receptor Inhibitors
1 drugsAbout CysLT1 receptor
The cysteinyl leukotriene receptor 1 (CysLT1) is a G protein-coupled receptor involved in inflammatory responses, especially in the respiratory system. It mediates the effects of leukotrienes, leading to bronchoconstriction, mucus production, and airway inflammation.
As a clinically validated target, CysLT1 receptor antagonism alleviates symptoms of asthma and allergic rhinitis. Currently, there is no genetic evidence available linking CysLT1 to specific diseases, warranting further investigation into its genetic associations.
CysLT1 is targeted by one FDA-approved drug, SINGULAIR (montelukast), a small molecule used for respiratory diseases. Merck is the primary company in this space, having developed SINGULAIR, which was first approved in 1998.
Top CysLT1 receptor Drugs
Merck is the leading company with the only approved drug, SINGULAIR, targeting CysLT1.
High market concentration suggests significant entry barriers; consider strategic partnerships to compete effectively.
CysLT1 receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets CysLT1 receptor, using small molecule modality.
Explore alternative modalities like antibodies or biologics to differentiate from existing small molecule therapies.
CysLT1 receptor Clinical Trials 98 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on CysLT1 receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 25 | 23 | 1 | 1 | 96% |
| Phase 2 | 30 | 21 | 1 | 8 | 95% |
| Phase 3 | 16 | 10 | 3 | 3 | 77% |
| Phase 4 | 27 | 20 | 2 | 4 | 91% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
CysLT1 receptor Drug Approval Timeline (1998 - 1998)
The first and only drug, SINGULAIR, was approved in 1998, indicating a long period without new approvals.
The lack of recent approvals suggests potential saturation or challenges in developing new CysLT1-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 72 (25 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on CysLT1 receptor. A trial counts if an approved drug acting on CysLT1 receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.